54 results about "Collagen i" patented technology

The invention relates to a recombinant I-type humanized collagen with crosslinking property as well as a preparation method and application thereof, and belongs to the technical field of recombinant proteins. The invention relates to recombinant I-type humanized collagen with crosslinking property. The amino acid sequence of the recombinant I-type humanized collagen comprises an amino acid sequence as shown in SEQ ID No.1 or a derivative amino acid sequence with the sequence identity of more than 90% with the sequence as shown in SEQ ID No.1; the recombinant I-type humanized collagen has a triple helix structure. A complete triple helix structure can be efficiently expressed, and the hydrogel has efficient cross-linking capability, so that the hydrogel can be efficiently and stably formed through cross-linking.

The invention relates to the technical field of biological medicine, in particular to I-type humanized collagen as well as a preparation method and application thereof. The amino acid sequence of the type I humanized collagen prepared by the invention is shown as a sequence SEQ ID NO. 1 (HTGAWGKTVIEYKTTKTSRLVMGFXGPKGAA, wherein X is hydroxyproline). The invention also discloses a preparation method of the type I humanized collagen. The I-type humanized collagen contains essential amino acids and semi-essential amino acids of a human body, promotes proliferation of human skin fibroblasts, up-regulates expression of elastin, fibronectin and collagen I genes, and has the effects of interacting with endothelial cells and osteoblasts, promoting creeping and growth of the osteoblasts, and promoting the growth of the osteoblasts. And the interaction between osteoblasts and collagen is promoted. Therefore, the I-type humanized collagen can be widely applied to orthopedic sports materials and has application prospects in the fields of medical cosmetology and sports medicine materials.

The invention belongs to the technical field of cosmetics, and provides an anti-wrinkle composition, application thereof and cosmetics. The composition provided by the invention comprises acetylated sodium hyaluronate and acetyl hydroxyproline, and the mass part ratio of the acetylated sodium hyaluronate to the acetyl hydroxyproline is (0.2-40): 1. In the composition provided by the invention, the acetylated sodium hyaluronate and the acetyl hydroxyproline have a synergistic anti-wrinkle effect, and the effect of the composition is obviously greater than the sum of the effects of the acetylated sodium hyaluronate and the acetyl hydroxyproline which are independently used in the aspect of promoting the synthesis of the fibroblast collagen I. When the composition with the synergistic anti-wrinkle effect provided by the invention is applied to preparation of cosmetics, the use amount of acetyl hydroxyproline can be reduced, so that the cost is reduced, and meanwhile, remarkable anti-wrinkle and anti-aging effects are obtained.

The invention discloses an application of eclipta source extracellular vesicles. The extracellular vesicles are extracted from the eclipta by adopting an overspeed combined ultrafiltration centrifugation method, and the extracted vesicles are complete in morphology and good in dispersity, and have the characteristics of high yield, high separation speed, low cost and easiness in large-scale production. The extracted vesicles can be successfully taken by animal cells. The yerbadetajo herb alcohol extract has the advantages that the yerbadetajo herb alcohol extract has antioxidant and anti-aging effects after being taken in, ultraviolet-induced matrix metalloproteinase 1 (MMP1) expression can be obviously reduced, collagen I (COL-I) generation can be promoted, ultraviolet-induced skin light aging can be improved, and the effect is better than that of the yerbadetajo herb alcohol extract, so that the yerbadetajo herb alcohol extract can be used for preparing the skin The eclipta-derived extracellular vesicles provided by the invention provide a new strategy for skin aging and anti-aging treatment.

The invention relates to a preparation method and application of novel rhizoma bletillae glucomannan. The preparation method of the rhizoma bletillae glucomannan comprises the following steps: 1, drying, crushing and sieving rhizomes of a raw material rhizoma bletillae; 2, putting the crushed and sieved rhizoma bletillae into ethanol for degreasing; 3, obtaining crude polysaccharide through a distilled water ice bath ultrasonic extraction technology and an ethanol precipitation technology; 4, separating and purifying through a DEAE-52 cellulose column and a G-150 gel column to obtain the high-purity rhizoma bletillae homogeneous polysaccharide BsPsIII1-1, namely the rhizoma bletillae glucomannan; 5, carrying out semipermeable membrane dialysis on the BsPsIII1-1 to remove salt, and carrying out freeze drying; and 6, carrying out chemical analysis on the obtained BsPsIII1-1. According to the preparation method and the application of the novel rhizoma bletillae glucomannan, animal experiments show that BsPsIII1-1 can significantly improve CCl4 induced mouse liver tissue injury, reduce serum ALT and AST levels, effectively relieve oxidative stress by reducing MDA content and increasing GSH level, and significantly inhibit hepatic fibrosis by down-regulating expression of alpha smooth muscle actin (alpha-SMA) and collagen I (COL-1).

A phosphodiesterase type 5 inhibitor is used in the preparation of a medicament for resisting fibrotic diseases. Experiments in animal models of ischemia-reperfusion (UIRI)-induced renal fibrosis, unilateral ureteral obstruction (UUO)-caused kidney fibrosis and idiopathic pulmonary fibrosis show that a PDE5 inhibitor such as tadalafil, sildenafil and vardenafil can significantly inhibit the expression of multiple fibrosis iconic proteins such as fibronectin, collagen I, renal injury molecule-1, and α-skeletal muscle actin in UIRI and UUO renal fibrosis lesions, improves glomerulopathy, degree of renal tubular distension, renal interstitial collagen fiber deposition and inflammatory cell infiltration, reduces the fibrotic area within the lesion, and significantly inhibits the progression of renal fibrosis; and the PDE5 inhibitor can significantly improve smooth muscle proliferation and inflammatory cell infiltration in bronchioles and pulmonary arterioles of idiopathic pulmonary fibrosis lesion, improve damage condition of alveolar tissue, and significantly inhibit the progression of pulmonary fibrosis.

The invention relates to the technical field of biological medicines, in particular to application of an MAPK1IP1L gene or an MAPK1IP1L protein serving as an action target to preparation of a medicine for treating chronic kidney disease. According to the invention, the MAPK1IP1L gene overexpression (MAPK1IP1L OE) HK2 cell is constructed, and compared with a group in which the HK2 cell is not treated, the MAPK1IP1L OE has the advantage that the protein expression levels of FN, Collagen I, Vimentin and alpha-SMA are obviously reduced. Therefore, the chronic kidney disease can be improved and treated by overexpressing the MAPK1IP1L gene. Therefore, the invention relates to the application of the MAPK1IP1L gene or the MAPK1IP1L protein as the action target spot in preparation and / or screening of the medicine for treating the chronic kidney disease.

The invention discloses an anti-aging composition as well as a preparation method and application thereof. The composition is prepared from the following components in parts by weight: 10 to 50 parts of ergothioneine; 5 to 25 parts of coenzyme Q10; 50 to 150 parts of 3-SL; 50 to 150 parts of collagen tripeptide; 100 to 500 parts of NAD (nicotinamide adenine dinucleotide); and 50 to 150 parts of glutathione. According to the anti-aging composition disclosed by the invention, various functional components such as the ergothioneine, the coenzyme Q10, the 3SL, the collagen tripeptide, the NAD < + > and the glutathione are reasonably proportioned, so that the anti-aging composition shows a remarkable synergistic anti-aging effect in in-vitro and in-vivo experiments. The anti-aging composition can enhance the cell antioxidant capacity, reduce the active oxygen level and promote the expression of collagen I and SIRT1, and compared with a single component or a non-optimized combination, the anti-aging effect is remarkably improved.

The present invention relates to an azolo compound of Formula (I) for use in the treatment of fibrosis, wherein the azolo compounds normalizes collagen I mRNA-levels of TGFB-activated fibroblasts and reverses collagen production to the normal levels that are seen in fibroblasts that are not stimulated.

The present invention relates to methods of immunoassay for detecting a biomarker which is an MMP-cleaved fragment of collagen type-I and its use in detecting and / or monitoring diseases such as kidney disease and diseases of the cardiovascular system including the heart.

The invention discloses a method for scar-free healing in treatment of wounds / wounds by miR-185-5p, relates to the field of biological medicine and plastic surgery and beauty repair, and comprises application of scar-free healing in acute / subacute / chronic wounds related to any skin injury (including burn, laceration, bruise, operation, perforation and vaccination) of deep dermis. Wound healing is a series of complex and elaborately-planned overlapping stages arranged according to a time sequence, wherein the stages comprise four stages of hemostasis, inflammation, proliferation and remodeling. No matter at any stage, the skin stability after wound healing and whether scars are formed or not can be directly influenced. The miR-185-5p is used in an animal skin model caused by an acute wound, so that the wound healing time is integrally shortened, the reepithelization formation of the wound is promoted, the number of skin appendages is increased, and the regeneration of hair follicles is promoted. The secretion amount of the collagen I is reduced, and the formation of the collagen III is improved.

The present invention relates to an azolo compound of Formula I for use in the treatment of fibrosis, wherein the azolo compounds normalizes collagen I mRNA-levels of TGFB-activated fibroblasts and reverses collagen production to the normal levels that are seen in fibroblasts that are not stimulated.

The invention discloses an oligopeptide composition, a recombinant polypeptide chain, a recombinant nucleic acid molecule and application. The oligopeptide composition comprises at least one oligopeptide, the amino acid sequence of the oligopeptide is the amino acid sequence of an active domain of HAPLN1 protein, and the oligopeptide composition is used for improving the expression quantity of fibroblasts on the HAPLN1 protein and collagen I.

The invention belongs to the technical field of medical chemistry, and particularly relates to a polycyclic polyketone derivative as well as a preparation method and application thereof in treating hepatic fibrosis. Six polycyclic polyketone compounds are obtained from a fungus M. arundinis HL1 separated from a marine sample in Huilaxian County, Guangdong Province, the series of compounds can significantly inhibit expression of FN, Collagen I, alpha-SMA and other fibrosis-related factors in hepatic stellate cells LX-2, and the compound 2 has a significant inhibition effect at a concentration of 40 [mu] mol / L and has no significant toxicity. And the compound 2 reduces the p-Smad2 / 3 level through dose dependence, does not influence the total Smad2 / 3 level, and plays an anti-fibrosis role by inhibiting a TGF-beta / Smad signal channel. The series of compounds, especially the compound 2, are expected to become anti-hepatic fibrosis candidate drugs, and provide a brand new chemical skeleton for research and development of low-toxicity and high-efficiency anti-hepatic fibrosis drugs.

The invention discloses a new application of benzbromarone or pharmaceutically acceptable salt thereof in preparation of a medicine for treating pulmonary fibrosis. The invention belongs to the technical field of medicine. Experimental results show that the benzbromarone can significantly reduce collagen deposition and inflammatory infiltration in lung tissues, reduce fibrosis area, improve lung functions of patients with pulmonary fibrosis, inhibit lung fibroblast activation and inhibit fibrosis progress. The action mechanism of the gene is related to inhibition of expression of BAG2, FN1, Collagen I and protein. The invention provides a brand new medicine choice for treating pulmonary fibrosis, has the unique advantage of new use of old medicine, and has the potential of short research and development period, known safety and definite curative effect. Meanwhile, the invention further expands the application of benzbromarone in preparation of the protein inhibitor and the in-vitro reagent.

The application discloses application of sibiricose A in preparation of products for promoting skin wound repair and regeneration. The application finds through experiments that sibiricose A can promote proliferation and migration of fibroblasts and vascular endothelial cells, promote lumen formation of vascular endothelial cells, and promote fibroblasts to secrete collagen I, can accelerate wound healing, promote more blood vessels and collagen to be generated, reduce secretion of pus and inflammatory substances, has the ability to promote skin wound repair and treat chronic ulcers, and provides an effective way for skin wound repair and regeneration, especially for repair and regeneration of diabetic refractory wounds.

Provided are preparation methods for an islet extracellular matrix scaffold and a biomimetic islet organoid. The scaffold is a gel, and the gel contains 3-5 mg / mL Collagen I, 3-5 mg / mL Collagen IV, and 0.8-1.2 mg / mL Laminin. For the scaffold, Collagen I, Collagen IV, and Laminin are simultaneously selected as extracellular matrix components, which have relatively strong interactions with islet cells, and effectively promote the islet cells and enhance insulin secretion function stimulated by glucose after binding to the islet cells. Collagen VI can also be used. Collagen VI can act on the islet cells to effectively enhance the survival of the islet cells and the insulin secretion function stimulated by glucose. The gel can form a relatively intact network structure without needing to use a cross-linking agent, thereby enhancing the support capacity for the islet organoid.

The application belongs to the technical field of medical treatment and discloses a cancer prognosis marker combination and application thereof, which comprises the following markers: CD68, PD-L1, PAN-CK, HLA-DR, CD45, CD11c and Collagen I. The cancer prognosis evaluation model trained by using the 7-marker combination exhibits superior prognosis accuracy compared to a model relying on high-dimensional multi-omics data. The application proposes a multiple immunohistochemistry (mIHC) cancer prognosis evaluation detection product based on the above-mentioned cancer prognosis marker combination. Satisfactory prognosis results are achieved by using only two five-marker combinations. The method exhibits high accuracy in predicting the survival of gastric cancer patients, so that it becomes a low-cost, high-benefit and scalable solution for other cancers.

The application discloses application of extracellular vesicles from Eclipta prostrata L. The extracellular vesicles are extracted from Eclipta prostrata L. by using ultracentrifugation and ultrafiltration, and the extracted vesicles are complete in appearance and good in dispersibility, and have the characteristics of high yield, fast separation, low cost and easy scaling. The extracted vesicles can be successfully taken by animal cells. After being taken, the vesicles play the roles of antioxidation and anti-aging, can significantly reduce ultraviolet-induced matrix metalloproteinase 1 (MMP1) expression, promote collagen I (COL-I) generation, improve ultraviolet-induced skin photoaging, and the effect is stronger than that of Eclipta prostrata L. alcohol extract, so that the extracellular vesicles from Eclipta prostrata L. provide a new strategy for skin aging and anti-aging treatment.

This invention provides a gardenia polysaccharide, its preparation method, and its application in the preparation of drugs for treating pulmonary fibrosis, relating to the fields of traditional Chinese medicine extracts and biomedical technology. This invention extracts a novel polysaccharide structure, GP121, from gardenia. The extraction method for GP121 provided by this invention is simple, with high polysaccharide extraction rate and low production cost. This invention further studies the anti-pulmonary fibrosis bioactivity of GP121 at the cellular level. The results show that GP121 provided by this invention can delay the fibrosis process of MRC-5 cells induced by TGF-β1, thereby slowing the fibrosis process by inhibiting the phosphorylation of Smad3 protein and thus reducing the expression of α-SMA, Collagen I, and FN proteins. GP121 provided by this invention can serve as a potential therapeutic drug for pulmonary fibrosis, providing a new application of gardenia polysaccharide in the treatment of pulmonary fibrosis.

The present invention relates to methods of immunoassay for detecting a biomarker which is an MMP-cleaved fragment of collagen type-I and its use in detecting and / or monitoring diseases such as kidney disease and diseases of the cardiovascular system including the heart.

The present invention discloses the application of anti-aging repair polypeptides in cosmetics, and specifically relates to the technical field of cosmetics. The anti-aging repair polypeptides of the present invention delay and inhibit the synthesis of interleukin-6 through multiple mechanisms of action, stimulate the synthesis of laminin V and collagen IV and VII, promote the synthesis of collagen I, and inhibit the activity of acetylcholine receptors, calcium, sodium, potassium and other ion channels. These effects together make the skin firm and elastic, reduce wrinkles, sagging skin and uneven skin color, and repair the skin and relax muscles to improve and reduce wrinkles.

The invention discloses a novel application of an anti-platelet drug prasugrel or a pharmaceutically acceptable salt thereof in preparation of a drug for treating and / or preventing hepatic fibrosis. The invention finds that prasugrel can inhibit expression levels of Asporin, alpha-SMA and Collagen I in hepatic fibrosis tissues, effectively inhibit activation of hepatic stellate cells and relieve fibrosis progress, so that the diameter of hepatic fibrosis portal vein is reduced, hepatic echo is weakened, the hepatic tissue structure is improved, and inflammatory cell infiltration and collagen deposition are reduced. Therefore, the prasugrel has the effect of preventing and / or treating the hepatic fibrosis, a brand new treatment strategy is provided for the hepatic fibrosis, and the new application of the prasugrel is developed.

The invention provides a preparation for promoting regeneration of skin fibroblasts and application of the preparation, and belongs to the technical field of cell biology. The preparation comprises two parts: a first culture medium for adherent culture, which contains resveratrol, melatonin, quercetin and other protective components; and the second culture medium is used for amplification and subculture and contains regeneration stimulants such as Angiotensin 1-7 and PDGF (Platelet Derived Growth Factor). Experimental results show that compared with a traditional serum-containing culture medium, the preparation provided by the invention can significantly improve the proliferation and migration of skin fibroblasts and the expression ability of collagen I. Therefore, the invention provides a cell culture scheme with definite components and excellent performance, and the cell culture scheme can be used for preparing medicines or products in the fields of skin repair, aging resistance and the like.

The application discloses a new application of 3-HPPA in preparing a drug for treating myocardial infarction. By means of modern pharmacological research methods, it is first confirmed that 3-HPPA has a significant myocardial protective effect. Experimental research shows that 3-HPPA can significantly improve the heart function of a myocardial infarction mouse induced by coronary artery ligation, improve the left ventricular ejection fraction and the short axis shortening rate, and reduce the infarction area; meanwhile, 3-HPPA can significantly inhibit the gene expression of a heart failure marker BNP, and down-regulate the expression levels of inflammatory factors IL-6, TNF-alpha and fibrosis related factors TGF-beta and Collagen I. Further mechanism research shows that 3-HPPA also plays an anti-inflammatory, anti-fibrosis and anti-apoptosis role. The application discloses the action characteristics of 3-HPPA in multi-target intervention of the pathological process of myocardial infarction, provides an important candidate compound for development of a new type of anti-myocardial infarction drug, and has a wide clinical application prospect.

The present invention discloses a 3D cell culture method for ultra-high resolution sub-organelle imaging research and its application, which comprises the following steps: Step (1): Drop the collagen I dilution solution onto the surface of the glass substrate for pre-incubation to form a pre-incubation layer; Step (2): Lay the collagen I and culture medium mixture on the surface of the pre-incubation layer for incubation to enable the collagen I to gel and form a network layer as the sedimentation layer; Step (3): Add the collagen I and cell mixture to the surface of the sedimentation layer for incubation to enable the collagen I to gel; Add cell culture medium and place it in an incubator for 5-7 days to allow the cells to grow and spread, complete the 3D cell culture, and form a 3D cell network layer. Through ultra-high resolution sub-organelle imaging, the sub-organelle structure can be presented, and the intracellular endocytosis kinetics of nanoparticles can be characterized and analyzed in real time for a long time.

The invention provides recombinant II-type collagen and application thereof in blood coagulation and tissue regeneration, and relates to the technical field of genetic engineering. The recombinant II type collagen realizes recombinant expression in pichia pastoris, and verifies that the recombinant expression protein can be self-assembled to form a triple helix structure and has no biotoxicity. The invention also provides an application of the prepared recombinant II-type collagen in promoting blood coagulation and fibroblast differentiation, shows the blood coagulation capability superior to that of a commercial blood coagulation agent rat tail collagen I, and has huge value and potential in the fields of cosmetics, medicine and tissue engineering.

The invention discloses application of a phenolic acid derivative or a salt thereof in treatment of osteoarticular degenerative diseases, and particularly relates to a compound shown in the following formula A, the invention also relates to application of the pharmaceutically acceptable salt, the optical isomer, the crystal form, the hydrate, the solvate or the prodrug thereof in preparation of a pharmaceutical composition for treating or preventing degeneration of bone and / or arthritis. The compound provided by the invention can increase the generation of bone tissue collagen I, enhance the osteogenesis of bone tissues, increase the generation of articular cartilage collagen II and delay subchondral bone remodeling, so that the effect of protecting articular cartilage is achieved, and therefore, the compound can be used for preparing medicines for treating and / or preventing bone and joint degenerative diseases. # imgabs0 #

The invention relates to the technical field of biological medicines, and mainly relates to application of tenascin-C (Tenascinin-C, TNC) as a prevention and / or treatment target in silicosis pulmonary fibrosis. The technical problem to be solved by the invention is to provide a new target selection for prevention and / or treatment of silicosis and pulmonary fibrosis. According to the technical scheme for solving the technical problem, the invention provides the application of the TNC as a target spot for preventing and / or treating silicosis pulmonary fibrosis. It is found that TNC is highly expressed in silicosis pulmonary fibrosis lung tissue, and expression of extracellular matrix genes and protein of human lung fibroblasts can be increased; the invention further finds that the expression of Collagen I and Fibronectin in the fibroblast can be obviously reduced by knocking down the Tnc in the lung tissue fibroblast, so that the progress of pulmonary fibrosis is inhibited. The invention provides a new target selection for prevention and / or treatment of silicosis pulmonary fibrosis, and has a good application prospect.

The invention belongs to the technical field of polysaccharides, and particularly discloses application of sulfated seaweed polysaccharides in preparation of anti-hepatic fibrosis drugs. According to a structural unit of the seaweed sulfated polysaccharide SPW-05-S2, 1, 4-beta-glucuronic acid and 1, 2-alpha-mannose are alternately connected to form a main chain, mannose, xylose, galactose and fucose form branch chains, the branch chains are located on the C-6 site and the C-3 site of the 1, 2-alpha-mannose, and the branch chains are located on the C6 site and the C-3 site of the 1, 2-alpha-mannose. The branches consist of galactose residues, xylose residues, mannose residues and fucose residues. In-vitro experiments prove that the polysaccharide can be used for remarkably inhibiting the expression of fibrosis related proteins (Fibronectin, Collagen I and alpha-smooth muscle actin), and can be used for remarkably inhibiting the expression of the fibrosis related proteins (Fibronectin, Collagen I and alpha-smooth muscle actin). Meanwhile, the surface plasmon resonance technology finds that the polysaccharide can be combined with PI3K protein. Therefore, the polysaccharide has a potential anti-hepatic fibrosis effect and is expected to become a candidate saccharide drug for treating hepatic fibrosis.